{
  "url": "https://www.defenseworld.net/2025/04/09/aeterna-zentaris-nasdaqaezs-coverage-initiated-by-analysts-at-stocknews-com.html",
  "title": "Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated by Analysts at StockNews.com - Defense World",
  "date_of_publish": "2025-04-09T06:36:58+00:00",
  "author": "Defense World Staff",
  "site_name": "Defense World",
  "tags": [
    "NASDAQ:AEZS",
    "Aeterna Zentaris,NASDAQ:AEZS,AEZS,Medical,Initiated Coverage,StockNews.com"
  ],
  "content": "Aeterna Zentaris (NASDAQ:AEZS) Coverage Initiated by Analysts at StockNews.com Posted by on Apr 9th, 2025 Get Aeterna Zentaris alerts: Aeterna Zentaris Price Performance opened at $2.43 on Wednesday. The firm has a market capitalization of $4.36 million, a P/E ratio of -0.16 and a beta of 1.55. The business has a 50 day simple moving average of $2.90 and a 200 day simple moving average of $3.15. Aeterna Zentaris has a 12-month low of $3.96 and a 12-month high of $12.00. Aeterna Zentaris Company Profile ( ) Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. Further Reading Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with ."
}